CoLucid Pharmaceuticals Announces Achievement of Both

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
CoLucid Pharmaceuticals Announces Achievement of Both Primary and Key Secondary Endpoints in the SAMURAI Phase 3 Pivotal Trial of Lasmiditan in Migraine
  • 100 mg and 200 mg doses of lasmiditan efficacious on headache pain freedom and most bothersome symptom free at the two-hour time point (p < 0.001)
  • Lasmiditan was well tolerated with no significant difference in cardiovascular adverse events in patients dosed with lasmiditan vs. placebo
  • SAMURAI conducted under Special Protocol Assessment agreement with FDA
  • Conference call being held Tuesday, September 6, 2016 at 9:00 a.m. EDT

CAMBRIDGE, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD ), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of migraine in adults, with or without aura, announced today that its Phase 3 pivotal study evaluating lasmiditan, the SAMURAI study, achieved both the primary and key secondary efficacy endpoints with statistical significance (p < 0.001). Lasmiditan was also well tolerated. SAMURAI was a randomized, double-blind, placebo-controlled parallel group study designed to evaluate the efficacy and safety of lasmiditan (100 mg and 200 mg) in comparison to placebo. SAMURAI is the first of two Phase 3 pivotal trials of lasmiditan, each being conducted under a Special Protocol Assessment agreement (“SPA”) with the U.S. Food and Drug Administration (“FDA”).

Efficacy

The primary endpoint of SAMURAI was the efficacy of lasmiditan (100 mg and 200 mg) in comparison to placebo based on freedom from migraine headache pain two hours after dosing. The key secondary endpoint was the efficacy of lasmiditan based on freedom from the most bothersome associated symptom (MBS) of migraine (nausea, phonophobia or photophobia) two hours after dosing. Data from the study were collected using electronic diaries during the treated attack. Beginning pre-dose, patients indicated their degree of headache pain on a 4-point scale: 0, no pain; 1, mild pain; 2, moderate pain; or 3, severe pain. Patients also indicated the presence or absence of nausea, phonophobia or photophobia, and at the pre-dose time point identified the associated symptom present that was “most bothersome.” At each time point assessment, patients were asked to indicate the degree of headache pain and the presence or absence of each associated symptom. The MBS endpoint was patient-centric and measured treatment effect of study drug on associated symptoms. Both the primary and key secondary endpoints of SAMURAI conform to the FDA’s Draft Guidance for Industry, Migraine: Developing Drugs for Acute Treatment , issued in October 2014.

PRIMARY ENDPOINT Lasmiditan 100mg Lasmiditan 200mg Placebo
% of patients migraine headache pain free at two hours   28.2 %   32.2 %   15.3 %
Odds Ratio (95% confidence interval) 2.2 (1.6 – 3.0) 2.6 (2.0 – 3.6)  
p-value p < 0.001 p < 0.001  
KEY SECONDARY ENDPOINT Lasmiditan 100mg Lasmiditan 200mg Placebo
% of patients MBS free at two hours   40.9 %   40.7 %   29.5 %
Odds Ratio (95% confidence interval) 1.7 (1.3 – 2.2) 1.6 (1.3 – 2.1)  
p-value p < 0.001 p < 0.001  

Adverse Events

Lasmiditan was well tolerated, with the majority of treatment emergent adverse events (TEAE) being nervous system related, and 91% of TEAE in lasmiditan treated patients being described as mild or moderate in nature. Importantly, there was not a significant increase in cardiovascular adverse events in patients who dosed with lasmiditan versus placebo. There were no serious adverse events in SAMURAI that were considered to be related to treatment. The following table sets forth the percentage of patients who experienced the specified adverse event within the safety population for each dose.

TEAE Lasmiditan 100mg (n=630) Lasmiditan 200mg (n=609) Placebo (n=617)
Dizziness 75 (11.9%) 94 (15.4%) 19 (3.1%)
Paresthesia 36 (5.7%) 46 (7.6%) 13 (2.1%)
Somnolence 33 (5.2%) 32 (5.3%) 14 (2.3%)
Nausea 16 (2.5%) 29 (4.8%) 9 (1.5%)
Fatigue 24 (3.8%) 18 (3.0%) 1 (0.2%)
Lethargy 12 (1.9%) 14 (2.3%) 1 (0.2%)
Vertigo 6 (1.0%) 2 (0.3%) 0

Demographics

2,231 patients were randomized at approximately 80 U.S. sites to participate in SAMURAI to treat a single migraine. Patients randomized had a mean age of 41.6 years, 83% were females, and 74% were Caucasian, with a mean migraine history of over 19 years.  Patients randomized experienced an average of over five migraines per month and suffered severe disability from migraine, with an average MIDAS (Migraine Disability Assessment) score of 31. Over 25% of patients randomized used prophylactic medication to reduce the frequency of migraine. 82% of patients randomized had multiple cardiovascular risk factors (CVRF) or cardiovascular conditions. The most prevalent CVRF were obesity, family history of coronary artery disease (CAD), smoking, hypertension, post-menopausal women, men over 40 years of age, hyperlipidemia and type 2 diabetes. The most prevalent cardiovascular conditions were arrhythmias, mitral valve disease, angina, atrial fibrillation, congestive heart failure, prior myocardial infarction, Raynaud’s disease, deep vein thrombosis, ischemic stroke, and cerebral infarction.

Analysis

In accordance with the SPA agreement for SAMURAI, the protocol pre-specified the analysis population as the modified intent to treat population (mITT). The mITT was defined in the protocol as all randomized patients who used at least one dose of study drug to treat a qualifying migraine attack and had any post-dose assessments. Patients were evaluated by the study medication to which they were randomized and a qualifying migraine attack was defined as a migraine treated with study drug within four hours of onset. Similar to other migraine clinical trials, approximately 30% of patients randomized in SAMURAI were not included in the mITT due to either a failure to dose a qualifying migraine during the trial, failure to use the electronic diaries for any time point assessment, or post-randomization ineligibility (clinical lab values). In the trial, 1,239 patients took at least one dose of lasmiditan versus 617 who took at least one dose of placebo. The mITT consisted of 1,021 patients who took lasmiditan and 524 who took placebo. Analysis was conducted using a one-sided test from a logistic regression model with treatment group and background use of medication to reduce the frequency of migraines as covariates.

Detailed results from SAMURAI will be presented at a symposium during the 5 th European Headache and Migraine Trust International Congress (EHMTIC 2016) taking place in Glasgow, Scotland on September 17, 2016.

Richard B. Lipton, MD, Edwin S. Lowe Professor and Vice Chair of Neurology, Professor of Epidemiology and Population Health at Albert Einstein College of Medicine and the Director, Montefiore Headache Center commented, “The SAMURAI study was successful from the twin perspectives of efficacy and tolerability. The treatment effects, even in patients with high levels of headache related disability, are impressive. The inclusion of patients with cardiovascular conditions and risk factors makes the safety profile compelling. Lasmiditan has the potential to become an important treatment option, particularly for migraine patients at high risk for cardiovascular disease.  In these patients, available acute migraine treatments such as triptans and ergot alkaloids may be contraindicated or have precautions and warnings because of their vasoconstrictive effects.”

“We have shown in SAMURAI that lasmiditan was effective in the acute treatment of migraine and well tolerated,” said Thomas P. Mathers, President and Chief Executive Officer of CoLucid.  “The study demographics represented the largest group of patients diagnosed and treated for migraine in the United States:  primarily woman over the age of 40.  Most patients, regardless of gender, had either CVRF or cardiovascular conditions. Currently, the use of prescription drug treatments in general, and triptans specifically, is less in these patients as compared to migraine patients with no CVRF. Given the convincing nature of the data, we are eager to complete the ongoing SPARTAN pivotal clinical trial, which uses the same endpoints and same statistical powering.”

Conference Call Details CoLucid will be hosting a conference call to discuss the top-line data from SAMURAI on Tuesday, September 6, 2016 @ 9 a.m. Eastern Daylight Time:

A replay of the conference call will be available through September 20, 2016:

  • US Investors: +1 877-870-5176
  • International: +1 858-384-5517
  • Replay PIN: 7859323

About Lasmiditan Lasmiditan has been designed for the acute treatment of migraine headaches in adults without the vasoconstrictor activity associated with previous generations of migraine therapies.  It selectively targets 5-HT1F receptors expressed in the trigeminal pathway.  Lasmiditan has been given the generic stem name “ditan,” which distinguishes it from other drug classes, including triptans, the current standard of care for migraine.

CoLucid is currently enrolling patients in a second pivotal Phase 3 clinical trial of lasmiditan oral tablets, SPARTAN. The objective of SPARTAN is to evaluate the safety and efficacy of lasmiditan (50 mg, 100 mg and 200 mg) in comparison to placebo two hours after dosing on freedom from migraine headache pain, which is the primary endpoint, and on freedom from the most bothersome associated symptom of migraine (nausea, phonophobia or photophobia), which is the key secondary endpoint. SPARTAN is a randomized, double-blind, placebo-controlled parallel group study.  The study is expected to treat a single migraine in up to 2,226 migraine patients with lasmiditan at approximately 140 sites in the United States, United Kingdom and Germany.  CoLucid expects that migraine patients enrolled in SPARTAN will include those who also have one or more cardiovascular risk factors, stable cardiovascular disease or known coronary artery disease (“CAD”). CoLucid has obtained an SPA agreement from the FDA for SPARTAN. Top-line results from SPARTAN are expected in 2H/2017.

CoLucid is also currently enrolling patients in GLADIATOR, a Phase 3 long-term, open-label trial of lasmiditan. GLADIATOR’s objective is to evaluate the safety and efficacy of lasmiditan, as well as resource utilization, functional outcomes and disability. Migraine patients who have completed CoLucid’s first Phase 3 pivotal trial, SAMURAI, as well as the Company’s second Phase 3 pivotal trial, SPARTAN, are eligible to enroll in GLADIATOR. GLADIATOR is expected to enroll up to a total of 2,580 patients, who will be randomized to receive 100 mg or 200 mg of lasmiditan, and treated for up to eight migraine attacks per month for one year. Based on the results of GLADIATOR, CoLucid intends to build an appropriate safety database to support a New Drug Application (“NDA”) for lasmiditan. At the time of the NDA submission, it is anticipated that there will be more than 15,000 patient exposures to lasmiditan in the entire clinical program.

About Migraine Migraine is the leading cause of disability among neurological disorders in the United States according to the American Migraine Foundation.  An estimated 36 million Americans suffer from migraine.  Migraine can be extremely disabling and costly, accounting for more than an estimated $20 billion in direct (e.g., doctor visits, medications) and indirect (e.g., missed work, lost productivity) expenses each year in the United States.

About CoLucid Pharmaceuticals, Inc. CoLucid was founded in 2005 and is developing lasmiditan oral tablets for the acute treatment of migraine headaches in adults and intravenous lasmiditan for the acute treatment of headache pain associated with migraine in adults in emergency room and other urgent care settings.

Forward-Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to CoLucid’s expectations for lasmiditan’s efficacy, anticipated marked demand, anticipated physician prescribing patterns, clinical trial enrollment goals and the timing of future clinical trials. Actual enrollment results, market demand, use of cash and other developments may occur that differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks that enrollment goals will not be met, trials may not be commenced or successful or may take longer to complete than anticipated, regulatory approval may not be obtained, physicians may not prescribe lasmiditan, and projected cash needs and expected financial results may be different. More information about the risks and uncertainties faced by CoLucid are contained in its periodic reports filed with the Securities and Exchange Commission. CoLucid disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Thomas Mathers Chief Executive Officer CoLucid Pharmaceuticals, Inc. (857) 285-6494 Hans Vitzthum Managing Director LifeSci Advisors, LLC. (212) 915-2568

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 205

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 286

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 327

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 207

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 221

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 330

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 299

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 287

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 264

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading

Top 5 Most Recently Viewed Articles

Challenges Ahead for Beyond Meat Despite Steady Price Target

Updated Category News Views 126

Beyond Meat's Current Stock Evaluation Piper Sandler continues to maintain its underweight rating on Beyond Meat Inc. (NASDAQ: BYND), keeping a price target steadfast at $3.00. This decision follows insights gained from their extensive Teen Survey, which engaged around 13,500 participants about their views on plant-based meat products. Survey Insights and Teen Trends The...

Continue Reading
LaFleur Minerals Paves the Way for Gold Mill Restart with Drilling

Updated Category News Views 194

LaFleur Minerals Focuses on Gold Production Enhancement Lafleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) is making significant strides towards initiating gold production with the recent commencement of a confirmation drilling program at its Swanson Gold Deposit. Located in a region rich in mineral resources, this initiative aims to gather essential data for a Preliminary...

Continue Reading
Understanding the Class Action Involving Integral Ad Science

Updated Category News Views 187

Important Update for Integral Ad Science Investors Integral Ad Science Holding Corp. (NASDAQ: IAS) investors should be aware of a crucial class action lawsuit. Legal representation is being provided by Kirby McInerney LLP, a trusted law firm, assisting affected individuals in navigating their rights and interests concerning this matter. Understanding the Class Action...

Continue Reading
Netformx and Ingram Micro Launch API to Enhance Sales Insights

Updated Category News Views 135

Netformx and Ingram Micro Team Up for an Innovative API Solution In an exciting partnership, Netformx, an industry leader in automation tools for IT solution providers, announced a new API collaboration with Ingram Micro. This integration aims to provide channel partners with a seamless view of their sales pipelines, enabling improved planning and enhanced deal...

Continue Reading
Purpose Healing Center Marks 8 Years of Service and Commitment

Updated Category News Views 185

Purpose Healing Center Marks 8 Years of Impact in Behavioral Health Purpose Healing Center, a prominent behavioral health and substance use treatment provider based in Scottsdale, Arizona, proudly celebrates its eighth anniversary of serving AHCCCS members statewide. The organization has made significant strides toward enhancing access to critical mental health services...

Continue Reading